Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.
PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company with a market cap of just $35 million, has unveiled a potentially transformative approach to the red-hot GLP-1 market that could significantly disrupt how weight loss and diabetes medications are delivered to patients.
Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) may have just positioned itself as a serious contender in the rapidly expanding obesity treatment market with impressive new preclinical data for its oral MC4R agonist PL7737. The results, announced today, demonstrate both rapid weight loss as a standalone therapy and enhanced effects when combined with GLP-1 medications like tirzepatide.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Reuters reported on Wednesday, citing three sources, that Starlink has cleared the only remaining regulatory hurdle for the satellite provider to enter the market.
The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less pathologically advanced in their disease.
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.
